Semin Thromb Hemost 2015; 41(02): 154-159
DOI: 10.1055/s-0035-1544162
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Incidence of Arterial Embolism in Patients on Treatment with Old and New Anticoagulants for Venous Thromboembolism

Paolo Prandoni
1   Department of Cardiovascular Sciences, Vascular Medicine Unit, University of Padua, Padua, Italy
,
Marta Milan
1   Department of Cardiovascular Sciences, Vascular Medicine Unit, University of Padua, Padua, Italy
,
Sofia Barbar
1   Department of Cardiovascular Sciences, Vascular Medicine Unit, University of Padua, Padua, Italy
,
Lucia Sarolo
1   Department of Cardiovascular Sciences, Vascular Medicine Unit, University of Padua, Padua, Italy
,
Chiara Piovella
1   Department of Cardiovascular Sciences, Vascular Medicine Unit, University of Padua, Padua, Italy
,
Raffaele Pesavento
1   Department of Cardiovascular Sciences, Vascular Medicine Unit, University of Padua, Padua, Italy
,
Franca Bilora
1   Department of Cardiovascular Sciences, Vascular Medicine Unit, University of Padua, Padua, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
17 February 2015 (online)

Abstract

The separate nature of venous and arterial thrombotic disorders has recently been challenged. Patients with venous thromboembolism (VTE) have an increased risk of subsequent symptomatic arterial cardiovascular events, the risk being higher in those with unexplained episodes. Among the implications of this association, there is the potential for old and new antithrombotic drugs to impact on the development of both venous and arterial cardiovascular events. According to the results of recent studies, aspirin in low doses, when administered for the long-term management of patients with unprovoked VTE, reduces by approximately 35% the risk of recurrent VTE while offering a considerable protection against the development of arterial cardiovascular events. By contrast, there is no room to expect a reduction in the risk of subsequent arterial cardiovascular events in patients treated with vitamin K antagonists (VKA) in comparison to patients in whom VKAs are discontinued. According to the results from recent randomized clinical trials, the likelihood of arterial cardiovascular events in patients on the novel direct factor Xa inhibitors is unlikely to differ from that of patients receiving conventional anticoagulation. As dabigatran has been associated with a slight increase in the risk of myocardial infarction over warfarin, its use should be discouraged in patients with coronary heart disease. The long-term use of low-dose apixaban beyond the first months in patients with unprovoked VTE may decrease the long-term risk of arterial, as well as venous, thrombotic events.

 
  • References

  • 1 You JJ, Singer DE, Howard PA , et al; American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e531S-e575S
  • 2 Vandvik PO, Lincoff AM, Gore JM , et al; American College of Chest Physicians. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e637S-e668S
  • 3 Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324 (7329) 71-86
  • 4 Warkentin TE. Aspirin for dual prevention of venous and arterial thrombosis. N Engl J Med 2012; 367 (21) 2039-2041
  • 5 Anderson DR, Dunbar MJ, Bohm ER , et al. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med 2013; 158 (11) 800-806
  • 6 Prandoni P, Bilora F, Marchiori A , et al. An association between atherosclerosis and venous thrombosis. N Engl J Med 2003; 348 (15) 1435-1441
  • 7 Hong C, Zhu F, Du D, Pilgram TK, Sicard GA, Bae KT. Coronary artery calcification and risk factors for atherosclerosis in patients with venous thromboembolism. Atherosclerosis 2005; 183 (1) 169-174
  • 8 Eliasson A, Bergqvist D, Björck M, Acosta S, Sternby NH, Ogren M. Incidence and risk of venous thromboembolism in patients with verified arterial thrombosis: a population study based on 23,796 consecutive autopsies. J Thromb Haemost 2006; 4 (9) 1897-1902
  • 9 Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008; 117 (1) 93-102
  • 10 Prandoni P, Piovella C, Pesavento R. Venous thromboembolism and arterial complications. Semin Respir Crit Care Med 2012; 33 (2) 205-210
  • 11 Migliacci R, Becattini C, Pesavento R , et al. Endothelial dysfunction in patients with spontaneous venous thromboembolism. Haematologica 2007; 92 (6) 812-818
  • 12 Mahmoodi BK, Gansevoort RT, Veeger NJ , et al; Prevention of Renal and Vascular End-stage Disease (PREVEND) Study Group. Microalbuminuria and risk of venous thromboembolism. JAMA 2009; 301 (17) 1790-1797
  • 13 Becattini C, Agnelli G, Prandoni P , et al. A prospective study on cardiovascular events after acute pulmonary embolism. Eur Heart J 2005; 26 (1) 77-83
  • 14 Prandoni P, Ghirarduzzi A, Prins MH , et al. Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. J Thromb Haemost 2006; 4 (9) 1891-1896
  • 15 Schulman S, Lindmarker P, Holmström M , et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost 2006; 4 (4) 734-742
  • 16 Bova C, Marchiori A, Noto A , et al. Incidence of arterial cardiovascular events in patients with idiopathic venous thromboembolism. A retrospective cohort study. Thromb Haemost 2006; 96 (2) 132-136
  • 17 Young L, Ockelford P, Milne D, Rolfe-Vyson V, Mckelvie S, Harper P. Post-treatment residual thrombus increases the risk of recurrent deep vein thrombosis and mortality. J Thromb Haemost 2006; 4 (9) 1919-1924
  • 18 Sørensen HT, Horvath-Puho E, Pedersen L, Baron JA, Prandoni P. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet 2007; 370 (9601) 1773-1779
  • 19 Spencer FA, Ginsberg JS, Chong A, Alter DA. The relationship between unprovoked venous thromboembolism, age, and acute myocardial infarction. J Thromb Haemost 2008; 6 (9) 1507-1513
  • 20 Klok FA, Mos IC, Broek L , et al. Risk of arterial cardiovascular events in patients after pulmonary embolism. Blood 2009; 114 (8) 1484-1488
  • 21 Becattini C, Vedovati MC, Ageno W, Dentali F, Agnelli G. Incidence of arterial cardiovascular events after venous thromboembolism: a systematic review and a meta-analysis. J Thromb Haemost 2010; 8 (5) 891-897
  • 22 Steele P. Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet 1980; 2 (8208-8209) 1328-1329
  • 23 Becattini C, Agnelli G, Schenone A , et al; WARFASA Investigators. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366 (21) 1959-1967
  • 24 Brighton TA, Eikelboom JW, Mann K , et al; ASPIRE Investigators. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012; 367 (21) 1979-1987
  • 25 Simes J, Becattini C, Agnelli G , et al; INSPIRE Study Investigators (International Collaboration of Aspirin Trials for Recurrent Venous Thromboembolism). Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. Circulation 2014; 130 (13) 1062-1071
  • 26 Schulman S, Granqvist S, Holmström M , et al; The Duration of Anticoagulation Trial Study Group. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997; 336 (6) 393-398
  • 27 Kearon C, Gent M, Hirsh J , et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340 (12) 901-907
  • 28 Agnelli G, Prandoni P, Santamaria MG , et al; Warfarin Optimal Duration Italian Trial Investigators. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 2001; 345 (3) 165-169
  • 29 Agnelli G, Prandoni P, Becattini C , et al; Warfarin Optimal Duration Italian Trial Investigators. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 2003; 139 (1) 19-25
  • 30 Kearon C, Akl EA, Comerota AJ , et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e419S-e494S
  • 31 Schulman S, Kearon C, Kakkar AK , et al; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361 (24) 2342-2352
  • 32 Schulman S, Kakkar AK, Goldhaber SZ , et al; RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129 (7) 764-772
  • 33 Bauersachs R, Berkowitz SD, Brenner B , et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363 (26) 2499-2510
  • 34 Büller HR, Prins MH, Lensin AW , et al; EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366 (14) 1287-1297
  • 35 Agnelli G, Buller HR, Cohen A , et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369 (9) 799-808
  • 36 Büller HR, Décousus H, Grosso MA , et al; Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369 (15) 1406-1415
  • 37 Schulman S, Kearon C, Kakkar AK , et al; RE-MEDY Trial Investigators; RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368 (8) 709-718
  • 38 Agnelli G, Buller HR, Cohen A , et al; PLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368 (8) 699-708
  • 39 Mak KH. Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. BMJ Open 2012; 2 (5) e001592
  • 40 Larsen TB, Rasmussen LH, Gorst-Rasmussen A , et al. Myocardial ischemic events in 'real world' patients with atrial fibrillation treated with dabigatran or warfarin. Am J Med 2014; 127 (4) 329-336.e4
  • 41 Clemens A, Fraessdorf M, Friedman J. Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment. Vasc Health Risk Manag 2013; 9: 599-615
  • 42 Artang R, Rome E, Nielsen JD, Vidaillet HJ. Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors. Am J Cardiol 2013; 112 (12) 1973-1979
  • 43 Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012; 172 (5) 397-402
  • 44 Douxfils J, Buckinx F, Mullier F , et al. Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 2014; 3 (3) e000515
  • 45 Dale B, Eikelboom JW, Weitz JI , et al. Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?. J Thromb Thrombolysis 2013; 35 (2) 295-301